Calocurb side effects: what the 24-week trial counted
Calocurb side effects, counted: the 24-week C4 trial's withdrawals and dose cuts for diarrhea and nausea, set against the brand pages' 'rare' and 'mild'.
Weight-loss supplements, weighed honestly.
Is Calocurb clinically proven? The C4 trial in numbers
Yes: one 24-week placebo-controlled trial, company-funded. Calocurb lost 4.3% vs 0.5% on placebo, a 3.8-point gap, at the label's maximum dose.
Lipofit Extreme Fat Burner 2.0: a fat burner recalled for an antidepressant and an industrial poison
FDA published a company announcement of a nationwide voluntary recall of Lipofit Extreme Fat Burner 2.0 over undeclared fluoxetine and 2,4-dinitrophenol. Two undeclared substances, two very different kinds of failure.
FORMI Weight Loss Complex, reviewed against the SlimBiome trial
Holland and Barrett's new own-label sachet is built on a fibre complex with a real open-access human trial behind it. That trial ran 150 minutes and never weighed anybody.
Two 'Esbelta' products, one named seller, and five substances the labels did not name
The FDA notified consumers about Esbelta Intense Loss and Esbelta Chupapanza Flat Belly on 18 August. This is not substitution and it is not underdosing — it is undeclared pharmaceutical ingredients, which no amount of label arithmetic would have caught.
Three more 'tejocote root' products, and the plant inside was yellow oleander
Reported on 12 August: three more online weight-loss products added to the FDA's yellow oleander alert, which now runs to 25. The failure here is not a dose problem — it is that the plant in the capsule was not the plant on the label.
SlimTide, reviewed: a dozen named ingredients and not one published amount
A July launch release for a probiotic-and-botanical weight-management capsule puts 'Supplement Facts' in its own headline. It names three bacterial strains and nine other ingredients, and attaches a number to none of them.
OxyElite returns with a new panel behind an old name
A famous stimulant brand is back for Europe with a fully disclosed panel. The disclosure is genuinely good; the case published for three of the inclusions is not.